Q4 2025 Nautilus Biotechnology Inc Earnings Call Transcript
Key Points
- Nautilus Biotechnology Inc (NAUT) unveiled the Voyager instrument at the US Human Proteome Organization conference, receiving positive feedback from researchers.
- The company launched its early access program for iterative mapping earlier than planned, indicating strong progress and customer interest.
- Nautilus Biotechnology Inc (NAUT) announced a collaboration with Weill Cornell Medicine Qatar and the Michael J. Fox Foundation, securing $1.2 million in funding.
- The company achieved a 23% decrease in operating expenses for Q4 2025 compared to the previous year, demonstrating strong financial discipline.
- Nautilus Biotechnology Inc (NAUT) ended the quarter with $156.1 million in cash equivalents and investments, providing a solid financial foundation.
- The early access program is not expected to drive significant revenue in the near term, with modest services revenue anticipated later in 2026.
- The company currently has no sales capacity, which may impact the speed of building a sales funnel and commercial launch readiness.
- Nautilus Biotechnology Inc (NAUT) expects operating expenses to increase by 15% to 20% in 2026 as they invest in platform development and commercial readiness.
- The primary revenue ramp from instrument sales is not expected until 2027, delaying significant revenue generation.
- The company anticipates a cash burn of $65 million to $70 million in 2026, which could impact financial stability if not managed carefully.
Good day and thank you for standing by. Welcome to the Nautilus Biotechnology Q4 2025 earnings conference call. (Operator Instructions).
Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Ji-Yon Yi, Investor Relations. Please go ahead.
Thank you. Earlier today, Nautilus released financial results for the quarter ended December 31, 2025. If you haven't received this news release, or if you'd like to be added to the company's distribution list, please send an email to [email protected]. Joining me today from Nautilus are Sujal Patel, Co-Founder and CEO, Parag Mallick, Co-Founder and Chief Scientist, and Anna Mowry, Chief Financial Officer.
Before we begin, I'd like to remind you that management will make statements during this call that are forward-looking within the meaning of the Federal securities laws. These statements involve material risks and uncertainties that
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
